Related Experiment Video
Updated: Jul 16, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis
V De Conca1, S Mesiti, E Vallarino
1EO Ospedali Galliera, Genova, Italy.
Abstract:
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. The response was maintained during four to six months, follow up in 41.4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction

